Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: Report on acute toxicity

Guy Soete, Stefano Arcangeli, Gert De Meerleer, Valeria Landoni, Valerie Fonteyne, Giorgio Arcangeli, Wilfried De Neve, Guy Storme

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate the early side effects of a short course hypofractionated radiotherapy regimen in prostate cancer. Materials and methods: Three institutions (IRE, AZ VUB, GUH) included 36 patients with T1-T3N0M0 prostate cancer in a phase II study. Patients were treated with 56 Gy in 16 fractions over 4 weeks. Early side effects were scored using the RTOG/EORTC criteria and the international prostate symptom index (IPSI) weekly during treatment and 1 and 2 months afterwards. The results were compared with two control groups of patients previously treated with conventional fractionation at AZ VUB (238 patients) and GUH (114 patients). Results: None of the patients experienced grade 3-4 toxicity. Grade 1-2 Gastro-intestinal (GI), grade 2 GI, grade 1-2 Genito-urinary (GU) and grade 2 GU toxicity occurred in 75%, 36%, 75% and 44% for the hypofractionation schedule. The corresponding figures were 25-44%, 6-29%, 47-53% and 16-44% for the control groups (p <0.01 for grade 1-2 GI and GU toxicity). Two months after treatment all GU and the majority of GI symptoms had resolved. The IPSI increased from (average ±1 SD) 5.6 ± 4 pre-treatment to 10.0 ± 6 during week 2-4 and had normalized (5.2 ± 4) two months after treatment. Conclusions: Though no grade 3-4 side effects were observed, the investigated schedule results in a marked increase of grade 1-2 early side effects as compared to a conventional regimen. Side effects resolved within two months post-treatment.

Original languageEnglish
Pages (from-to)78-81
Number of pages4
JournalRadiotherapy and Oncology
Volume80
Issue number1
DOIs
Publication statusPublished - Jul 2006

Fingerprint

Prostatic Neoplasms
Radiotherapy
Prostate
Appointments and Schedules
Therapeutics
Control Groups

Keywords

  • Hypofractionation
  • Prostate cancer
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Urology

Cite this

Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer : Report on acute toxicity. / Soete, Guy; Arcangeli, Stefano; De Meerleer, Gert; Landoni, Valeria; Fonteyne, Valerie; Arcangeli, Giorgio; De Neve, Wilfried; Storme, Guy.

In: Radiotherapy and Oncology, Vol. 80, No. 1, 07.2006, p. 78-81.

Research output: Contribution to journalArticle

Soete, Guy ; Arcangeli, Stefano ; De Meerleer, Gert ; Landoni, Valeria ; Fonteyne, Valerie ; Arcangeli, Giorgio ; De Neve, Wilfried ; Storme, Guy. / Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer : Report on acute toxicity. In: Radiotherapy and Oncology. 2006 ; Vol. 80, No. 1. pp. 78-81.
@article{5d1c532f755a429aaa3a20f9133a6990,
title = "Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: Report on acute toxicity",
abstract = "Purpose: To evaluate the early side effects of a short course hypofractionated radiotherapy regimen in prostate cancer. Materials and methods: Three institutions (IRE, AZ VUB, GUH) included 36 patients with T1-T3N0M0 prostate cancer in a phase II study. Patients were treated with 56 Gy in 16 fractions over 4 weeks. Early side effects were scored using the RTOG/EORTC criteria and the international prostate symptom index (IPSI) weekly during treatment and 1 and 2 months afterwards. The results were compared with two control groups of patients previously treated with conventional fractionation at AZ VUB (238 patients) and GUH (114 patients). Results: None of the patients experienced grade 3-4 toxicity. Grade 1-2 Gastro-intestinal (GI), grade 2 GI, grade 1-2 Genito-urinary (GU) and grade 2 GU toxicity occurred in 75{\%}, 36{\%}, 75{\%} and 44{\%} for the hypofractionation schedule. The corresponding figures were 25-44{\%}, 6-29{\%}, 47-53{\%} and 16-44{\%} for the control groups (p <0.01 for grade 1-2 GI and GU toxicity). Two months after treatment all GU and the majority of GI symptoms had resolved. The IPSI increased from (average ±1 SD) 5.6 ± 4 pre-treatment to 10.0 ± 6 during week 2-4 and had normalized (5.2 ± 4) two months after treatment. Conclusions: Though no grade 3-4 side effects were observed, the investigated schedule results in a marked increase of grade 1-2 early side effects as compared to a conventional regimen. Side effects resolved within two months post-treatment.",
keywords = "Hypofractionation, Prostate cancer, Radiotherapy",
author = "Guy Soete and Stefano Arcangeli and {De Meerleer}, Gert and Valeria Landoni and Valerie Fonteyne and Giorgio Arcangeli and {De Neve}, Wilfried and Guy Storme",
year = "2006",
month = "7",
doi = "10.1016/j.radonc.2006.06.005",
language = "English",
volume = "80",
pages = "78--81",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer

T2 - Report on acute toxicity

AU - Soete, Guy

AU - Arcangeli, Stefano

AU - De Meerleer, Gert

AU - Landoni, Valeria

AU - Fonteyne, Valerie

AU - Arcangeli, Giorgio

AU - De Neve, Wilfried

AU - Storme, Guy

PY - 2006/7

Y1 - 2006/7

N2 - Purpose: To evaluate the early side effects of a short course hypofractionated radiotherapy regimen in prostate cancer. Materials and methods: Three institutions (IRE, AZ VUB, GUH) included 36 patients with T1-T3N0M0 prostate cancer in a phase II study. Patients were treated with 56 Gy in 16 fractions over 4 weeks. Early side effects were scored using the RTOG/EORTC criteria and the international prostate symptom index (IPSI) weekly during treatment and 1 and 2 months afterwards. The results were compared with two control groups of patients previously treated with conventional fractionation at AZ VUB (238 patients) and GUH (114 patients). Results: None of the patients experienced grade 3-4 toxicity. Grade 1-2 Gastro-intestinal (GI), grade 2 GI, grade 1-2 Genito-urinary (GU) and grade 2 GU toxicity occurred in 75%, 36%, 75% and 44% for the hypofractionation schedule. The corresponding figures were 25-44%, 6-29%, 47-53% and 16-44% for the control groups (p <0.01 for grade 1-2 GI and GU toxicity). Two months after treatment all GU and the majority of GI symptoms had resolved. The IPSI increased from (average ±1 SD) 5.6 ± 4 pre-treatment to 10.0 ± 6 during week 2-4 and had normalized (5.2 ± 4) two months after treatment. Conclusions: Though no grade 3-4 side effects were observed, the investigated schedule results in a marked increase of grade 1-2 early side effects as compared to a conventional regimen. Side effects resolved within two months post-treatment.

AB - Purpose: To evaluate the early side effects of a short course hypofractionated radiotherapy regimen in prostate cancer. Materials and methods: Three institutions (IRE, AZ VUB, GUH) included 36 patients with T1-T3N0M0 prostate cancer in a phase II study. Patients were treated with 56 Gy in 16 fractions over 4 weeks. Early side effects were scored using the RTOG/EORTC criteria and the international prostate symptom index (IPSI) weekly during treatment and 1 and 2 months afterwards. The results were compared with two control groups of patients previously treated with conventional fractionation at AZ VUB (238 patients) and GUH (114 patients). Results: None of the patients experienced grade 3-4 toxicity. Grade 1-2 Gastro-intestinal (GI), grade 2 GI, grade 1-2 Genito-urinary (GU) and grade 2 GU toxicity occurred in 75%, 36%, 75% and 44% for the hypofractionation schedule. The corresponding figures were 25-44%, 6-29%, 47-53% and 16-44% for the control groups (p <0.01 for grade 1-2 GI and GU toxicity). Two months after treatment all GU and the majority of GI symptoms had resolved. The IPSI increased from (average ±1 SD) 5.6 ± 4 pre-treatment to 10.0 ± 6 during week 2-4 and had normalized (5.2 ± 4) two months after treatment. Conclusions: Though no grade 3-4 side effects were observed, the investigated schedule results in a marked increase of grade 1-2 early side effects as compared to a conventional regimen. Side effects resolved within two months post-treatment.

KW - Hypofractionation

KW - Prostate cancer

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=33746994052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746994052&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2006.06.005

DO - 10.1016/j.radonc.2006.06.005

M3 - Article

C2 - 16828910

AN - SCOPUS:33746994052

VL - 80

SP - 78

EP - 81

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 1

ER -